Agios Pharmaceuticals Inc stock is traded at $27.60, with a volume of 776,164. It is down -4.03% in the last 24 hours and down -24.67% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Previous Close:
$28.76
Open:
$28.01
24h Volume:
776,164
Relative Volume:
1.07
Market Cap:
$1.65B
Revenue:
$66.05M
Net Income/Loss:
-$422.60M
P/E Ratio:
-
EPS:
-$7.25
Net Cash Flow:
-$384.73M
1W Performance:
-12.63%
1M Performance:
-24.67%
6M Performance:
-3.16%
1Y Performance:
+12.33%
1-Day Range:
$27.43$29.14
1-Week Range:
$27.43$31.70
52-Week Range:
$23.00$44.09
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
617-649-8600Address
88 SIDNEY STREET, CAMBRIDGE, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS